Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma

Cancer Research

Volumn 59, Issue 17, 1999, Pages 4392-4399

  Glick, Richard D ^a   Swendeman, Steven L ^a   Coffey, Dennis C ^a   Rifkind, Richard A ^a   Marks, Paul A ^a   Richon, Victoria M ^a   La Quaglia, Michael P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE INHIBITOR; CINNAMIC ACID DERIVATIVE; ENZYME INHIBITOR; FAS ANTIGEN; FAS LIGAND; HEXAMETHYLENEBISACETAMIDE; HISTONE DEACETYLASE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA DEGRADATION; DNA DETERMINATION; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NEUROBLASTOMA; PRIORITY JOURNAL;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL DIVISION; CELL NUCLEUS; CINNAMATES; CYCLOHEXIMIDE; DNA FRAGMENTATION; ENZYME INHIBITORS; FAS LIGAND PROTEIN; HISTONE DEACETYLASES; HISTONES; HUMANS; MEMBRANE GLYCOPROTEINS; NEUROBLASTOMA; TUMOR CELLS, CULTURED;

EID: 0033199896     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Berthold, F. Overview: biology of neuroblastoma. In: C. Pochedly (ed.), Neuroblastoma: Tumor Biology and Therapy, pp. 1-30. Boca Raton, FL: CRC Press. 1998.
2. Black, C. T., and Atkinson, J. B. Neuroblastoma. Semin. Pediatr. Surg., 6: 2-10, 1997.
3. Castleberry, R. P. Chemotherapy of neuroblastoma. In: C. Pochedly (ed.), Neuroblastoma: Tumor Biology and Therapy, pp. 305-315. Boca Raton, FL: CRC Press, 1990.
4. Machin, G. Histogenesis and histopathology of neuroblastoma. In: C. Pochedly (ed.), Neuroblastoma, Clinical and Biological Manifestations, pp. 195-231. New York: Elsevier Biomedical, 1982.
5. Oue, T., Fukuzawa, M., Kusafuka, T., Kohmoto, Y., Imura, K., Nagahara, S., and Okada, A. In situ detection of DNA fragmentation and expression of bcl-2 in human neuroblastoma: relation to apoptosis and spontaneous regression. J. Pediatr. Surg., 31: 251-257, 1996.
6. Haas, D., Ablin, A. R., Miller, C., Zoger, S., and Matthay, K. K. Complete pathologic maturation and regression of stage IVS neuroblastoma without treatment. Cancer (Phila.), 62: 818-825, 1988.
7. Ikeda, H., Hirato, J., Akami, M., Suzuki, N., Takahashi, A., Kuroiwa, M., and Matsuyama, S. Massive apoptosis detected by in situ DNA nick end labeling in neuroblastoma. Am. J. Surg. Pathol., 20: 649-655, 1996.
8. Finklestein, J. Z., Krailo, M. D., Lenarsky, C., Ladisch, S., Blair, G. K., Reynolds, C. P., Sitarz, A. L., and Hammond, G. D. 13-cis-retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: report from the Childrens Cancer Study Group. Med. Pediatr. Oncol., 20: 307-311, 1992.
9. Ciccarone, V., Spengler, B. A., Meyers, M. B., Biedler, J. L., and Ross, R. A. Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages. Cancer Res., 49: 219-225, 1989.
10. Tsokos, M., Ross, R. A., and Triche, T. J. Neuronal, Schwannian and melanocytic differentiation of human neuroblastoma cells in vitro. Prog. Clin. Biol. Res., 175:55-68, 1985.
11. Piacentini, M., Piredda, L., Starace, D. T., Annicchiarico-Petnizzelli, M., Mattei, M., Oliverio, S., Farrace, M. G., and Melino, G. Differential growth of N- and S-type human neuroblastoma cells xenografted into scid mice. Correlation with apoptosis. J. Pathol., 180: 415-422, 1996.
12. Fulda, S., Friesen, C., Los, M., Scaffidi, C., Mier, W., Benedict, M., Nunez, G., Krammer, P. H., Peter, M. E., and Debatin, K. M. Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res., 57: 4956-4964, 1997.
13. Fulda, S., Sieverts, H., Friesen, C., Herr, I., and Debatin, K. M. The CD95 (APO-1/ Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res., 57: 3823-3829, 1997.
14. Sidell, N. Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. J. Natl. Cancer Inst., 68: 589-596, 1982.
15. Pahlman, S., Ruusala, A. I., Abrahamsson, L., Mattsson, M. E., and Esscher, T. Retinoic acid-induced differentiation of cultured human neuroblastoma cells: a comparison with phorbolester-induced differentiation. Cell Differ., 14: 135-144, 1984.
16. Gross, N., Beck, D., Favre, S., and Carrel, S. In vitro antigenic modulation of human neuroblastoma cells induced by IFN-γ, retinoic acid and dibutyryl cyclic AMP. Int. J. Cancer, 39: 521-529, 1987.
17. Thiele, C. J., Reynolds, C. P., and Israel, M. A. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature (Lond.), 313: 404-406, 1985.
18. Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., and Marks, P. A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. USA, 95: 3003-3007, 1998.
19. Ferreira, R., Magnaghi-Jaulin, L., Robin, P., Harel-Bellan, A., and Trouche, D. The three members of the pocket proteins family share the ability to repress E2F activity through recruitment of a histone deacetylase. Proc. Natl. Acad. Sci. USA, 95: 10493-10498, 1998.
20. Brehm, A., Miska, E. A., McCance, D. J., Reid, J. L., Bannister, A. J., and Kouzarides, T. Retinoblastoma protein recruits histone deacelylase to repress transcription. Nature (Lond.), 391: 597-601, 1998.
21. Wong, C. W., and Privalsky, M. L. Transcriptional repression by the SMRT-mSin3 corepressor: multiple interactions, multiple mechanisms, and a potential role for TFIIB. Mol. Cell. Biol., 18: 5500-5510, 1998.
22. David, G., Alland, L., Hong, S. H., Wong, C. W., DePinho, R. A., and Dejean, A. Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene, 16: 2549-2556, 1998.
23. Grignani, F., De Matteis, S., Nervi, C., Tomassoni, L., Gelmetti, V., Cioce, M., Fanelli, M., Ruthardt, M., Ferrara, F. F., Zamir, I., Seiser, C., Lazar, M. A., Minucci, S., and Pelicci, P. G. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukemia. Nature (Lond.), 391: 815-818, 1998.
24. Lin, R. J., Nagy, L., Inoue, S., Shao, W., Miller, W. H., Jr., and Evans, R. M. Role of the histone deacetylase complex in acute promyelocytic leukemia. Nature (Lond.), 391: 811-814, 1998.
25. He, L. Z., Guidez, F., Tribioli, C., Peruzzi, D., Ruthardt, M., Zelent, A., and Pandolfi, P. P. Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL. Nat. Genet., 18: 126-135, 1998.
26. Nagy, L., Kao, H. Y., Chakravarti, D., Lin, R. J., Hassig, C. A., Ayer, D. E., Schreiber, S. L., and Evans, R. M. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell, 89: 373-380, 1997.
27. Davie, J. R. Nuclear matrix, dynamic histone acetylation and transcriptionally active chromatin. Mol. Biol. Rep., 24: 197-207, 1997.
28. Kruh, J. Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol. Cell Biochem., 42: 65-82, 1982.
29. Calabresse, C., Venturini, L., Ronco, G., Villa, P., Chomienne, C., and Belpomme, D. Butyric acid and its monosaccharide ester induce apoptosis in the HL-60 cell line. Biochem. Biophys. Res. Commun., 195: 31-38, 1993.
30. Hague, A., Manning, A. M., Hanlon, K. A., Huschtscha, L. I., Hart, D., and Paraskeva, C. Sodium butyrate induces apoptosis in human colonic tumor cell lines in a p53-independent pathway: implications for the possible role of dietary fiber in the prevention of large-bowel cancer. Int. J. Cancer, 55: 498-505, 1993.
31. Conway, R. M., Madigan, M. C., Penfold, P. L., and Billson, F. A. Induction of apoptosis by sodium butyrate in the human Y-79 retinoblastoma cell line. Oncol. Res., 7: 289-297, 1995.
32. Carducci, M. A., Nelson, J. B., Chan-Tack, K. M., Ayyagari, S. R., Sweatt, W. H., Campbell, P. A., Nelson, W. G., and Simons, J. W. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin. Cancer Res., 2: 379-387, 1996.
33. Wang, X. M., Wang, X., Li, J., and Evers, B. M. Effects of 5-azacytidine and butyrate on differentiation and apoptosis of hepatic cancer cell lines. Ann. Surg., 227: 922-931, 1998.
34. Litvak, D. A., Evers, B. M., Hwang, K. O., Hellmich, M. R., Ko, T. C., and Townsend, C. M., Jr. Butyrate-induced differentiation of Caco-2 cells is associated with apoptosis and early induction of p21Waf1/Cip1 and p27Kip1. Surgery, 124: 161-170, 1998.
35. Archer, S., Meng, S., Wu, J., Johnson, J., Tang, R., and Hodin, R. Butyrate inhibits colon carcinoma cell growth through two distinct pathways. Surgery, 124: 248-253, 1998.
36. Nakano, K., Mizuno, T., Sowa, Y., Orita, T., Yoshino, T., Okuyama, Y., Fujita, T., Ohtani-Fujita, N., Matsukawa, Y., Tokino, T., Yamagishi, H., Oka, T., Nomura, H., and Sakai, T. Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J. Biol. Chem., 272: 22199-22206, 1997.
37. Nuydens, R., Heers, C., Chadarevian, A., De Jong, M., Nuyens, R., Cornelissen, F., and Geerts, H. Sodium butyrate induces aberrant τ phosphorylation and programmed cell death in human neuroblastoma cells. Brain Res., 688: 86-94, 1995.
38. Scheppach, W., Bartram, H. P., and Richter, F. Role of short-chain fatty acids in the prevention of colorectal cancer. Eur. J. Cancer, 31A: 1077-1080, 1995.
39. Yoshida, M., Kijima, M., Akita, M., and Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vim and in vitro by trichostatin A. J. Biol. Chem., 265: 17174-17179, 1990.
40. Yoshida, M., Nomura, S., and Beppu, T. Effects of trichostatins on differentiation of murine erythroleukemia cells. Cancer Res., 47: 3688-3691, 1987.
41. Ogryzko, V. V., Hirai, T. H., Russanova, V. R., Barbie, D. A., and Howard, B. H. Human fibroblast commitment to a senescence-like state in response to histone deacetylase inhibitors is cell cycle dependent. Mol. Cell. Biol., 16: 5210-5218, 1996.
42. Kijima, M., Yoshida, M., Sugita, K., Horinouchi, S., and Beppu, T. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J. Biol. Chem., 268: 22429-22435, 1993.
43. Huang, N., Katz, J. P., Martin, D. R., and Wu, G. D. Inhibition of IL-8 gene expression in Caco-2 cells by compounds which induce histone hyperacetylation. Cytokine, 9: 27-36, 1997.
44. Devedjian, J. C., Schaak, S., Garnet, L., Denis-Pouxviel, C., and Paris, H. Regulation of a 2A-adrenergic receptor expression in the human colon carcinoma cell line HT29: SCFA-induced enterocytic differentiation results in an inhibition of a 2C10 gene transcription. Proc. Assoc. Am. Physicians, 108: 334-344, 1996.
45. Dangond, F., and Gullans, S. R. Differential expression of human histone deacetylase mRNAs in response to immune cell apoptosis induction by trichostatin A and butyrate. Biochem. Biophys. Res. Commun., 247: 833-837, 1998.
46. Medina, V., Edmonds, B., Young, G. P., James, R., Appleton, S., and Zalewski, P. D. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res., 57: 3697-3707, 1997.
47. McBain, J. A., Eastman, A., Nobel, C. S., and Mueller, G. C. Apoptotic death in adenocarcinoma cell lines induced by butyrate and other histone deacetylase inhibitors. Biochem. Pharmacol., 53: 1357-1368, 1997.
48. Richon, V. M., Webb, Y., Merger, R., Sheppard, T., Jursic, B., Ngo, L., Civoli, F., Breslow, R., Rifkind, R. A., and Marks, P. A. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl. Acad. Sci. USA, 93: 5705-5708, 1996.
49. Ronca, F., Chan, S. L., and Yu, V. C. 1-(5-Isoquinolinesulfonyl)-2-methylpiperazine induces apoptosis in human neuroblastoma cells, SH-SY5Y, through a p53-dependent pathway. J. Biol. Chem., 272: 4252-4260, 1997.
50. Gorczyca, W., Gong, J., and Darzynkiewicz, Z. Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res., 53: 1945-1951, 1993.
51. Schulze-Osthoff, K., Ferrari, D., Los, M., Wesselborg, S., and Peter, M. E. Apoptosis signaling by death receptors. Eur. J. Biochem., 254: 439-459, 1998.
52. Nagata, S., and Golstein, P. The Fas death factor. Science (Washington DC), 267: 1449-1456, 1995.
53. Schneider, P., Bodmer, J. L., Holler, N., Mattmann, C., Scuderi, P., Terskikh, A., Peitsch, M. C., and Tschopp, J. Characterization of Fas (Apo-1, CD95)-Fas ligand interaction. J. Biol. Chem., 272: 18827-18833, 1997.
54. Runic, R., Lockwood, C. J., Ma, Y., Dipasquale, B., and Guller, S. Expression of Fas ligand by human cytotrophoblasts: implications in placentation and fetal survival. J. Clin. Endocrinol. Metab., 81: 3119-3122, 1996.
55. Caderni, G., Luceri, C., Lancioni, L., Tessitore, L., and Dolara, P. Slow-release pellets of sodium butyrate increase apoplosis in the colon of rats treated with azoxymethane, without affecting aberrant crypt foci and colonie proliferation. Nutr. Cancer, 30: 175-181, 1998.
56. Heerdt, B. G., Houston, M. A., and Augenlicht, L. H. Short-chain fatty acid-initiated cell cycle arrest and apoptosis of colonie epithelial cells is linked to mitochondrial function. Cell Growth Differ., 8: 523-532, 1997.
57. Rocchi, P., Ferreri, A. M., Simone, G., Granchi, D., Paolucci, P., and Paolucci, G. Growth inhibitory and differentiating effects of sodium butyrate on human neuroblastoma cells in culture. Anticancer Res., 12: 917-920, 1992.
58. Rocchi, P., Ferreri, A. M., Magrini, E., and Perocco, P. Effect of butyrate analogues on proliferation and differentiation in human neuroblastoma cell lines. Anticancer Res., 18: 1099-1103, 1998.
59. Daniel, P., Brazier, M., Cerutti, I., Fieri, F., Tardivel, I., Desmet, G., Baillet, J., and Chany, C. Pharmacokinetic study of butyric acid administered in vivo as sodium and arginine butyrate salts. Clin. Chim. Acta, 181: 255-263, 1989.
60. Miller, A. A., Kurschel, E., Osieka, R., and Schmidt, C. G. Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur. J. Cancer Clin. Oncol., 23: 1283-1287, 1987.
61. Newmark, H. L., and Young, C. W. Butyrate and phenylacetate as differentiating agents: practical problems and opportunities. J. Cell. Biochem., 22 (Suppl.): 247-253, 1995.
62. Fulda, S., Susin, S. A., Kroemer, G., and Debatin, K. M. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res., 58: 4453-4460, 1998.
63. Herr, I., Wilhelm, D., Bohler, T., Angel, P., and Debatin, K. M. Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. EMBO J., 16: 6200-6208, 1997.
64. Faris, M., Kokot, N., Latinis, K., Kasibhatla, S., Green, D. R., Koretzky, G. A., and Nel, A. The c-Jun N-terminal kinase cascade plays a role in stress-induced apoptosis in Jurkat cells by up-regulating Fas ligand expression. J. Immunol., 160: 134-144, 1998.
65. Owen-Schaub, L. B., Zhang, W., Cusack, J. C., Angelo, L. S., Santee, S. M., Fujiwara, T., Roth, J. A., Deisseroth, A. B., Zhang, W. W., and Kruzel, E. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell. Biol., 15: 3032-3040, 1995.
66. Muller, M., Scaffidi, C. A., Galle, P. R., and Krammer, W. S. The role of p53 and the CD95 (APO-1/Fas) death system in chemotherapy-induced apoptosis. Eur. Cytokine Netw., 9: 685-686, 1998.
67. Kuo, M. H., and Allis, C. D. Roles of histone acetyltransferases and deacetylases in gene regulation. BioEssays, 20: 615-626, 1998
68. Chan, H. S., DeBoer, G., Haddad, G., Gallie, B. L., and Ling, V. Multidrug resistance in pediatric malignancies. Hematol. Oncol. Clin. North Am., 9: 275-318, 1995.
69. Norris, M. D., Bordow, S. B., Marshall, G. M., Haber, P. S., Cohn, S. L., and Haber, M. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N. Engl. J. Med., 334: 231-238, 1996.
70. Warrell, R. P., Jr., He, L. Z., Richon, V., Calleja, E., and Pandolfi, P. P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst., 90: 1621-1625, 1998.